More news
Heat Biologics Appoints Damien Hallet as Vice President of CMC Development
By AccessWire, July 03, 2017, 07:00:00 AM EDT
Vote up AAA
DURHAM, NC / ACCESSWIRE / July 3, 2017 /Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, has announced the appointment of Damien Hallet as Vice President of Chemicals, Manufacturing and Controls (CMC).
"Damien has extensive technical and development expertise and I believe he is ideally suited to lead the next phase of growth across our development and manufacturing," said Jeff Wolf, CEO. "I am pleased to add him to our leadership team and I'm confident that he will continue his track record of success."
Mr. Hallet was promoted from his previous position as Senior Director of CMC. In this new role, he will be responsible for all aspects of development and manufacturing for the company's whole cell cancer immuno-therapy materials currently in clinical trials. He will also oversee the further development of the PTX-25 antibody from Heat's Pelican Therapeutics subsidiary.
Mr. Hallet has 17 years experience working in cell therapy and antibody development for such companies as Sanofi, Gencell SAS and UCB Pharma. He received his Masters of Advanced Studies in Industrial Microbiology from Ecole Doctorale de Toulouse, and a Biochemical Engineering degree from INSA de Toulouse, Grande Ecole.
"I am excited to be leading the CMC function within a company that has the potential to change the lives of cancer patients. Our allogeneic technology makes possible the development of scalable manufacturing processes and off-the-shelf treatments that could facilitate the access to our therapies across the globe," Hallet said. "We will continue to build our manufacturing efforts, while leading the development of next-generation capabilities to ensure our therapies are of the highest quality, safety and reliability for our clinical trials and the patient community."
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing therapies designed to activate a patient's immune system against cancer. Heat has generated highly specific T cell-stimulating therapeutic platform technologies, known as ImPACT and ComPACT. These technologies, in combination with other therapies such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms-of-action: robust activation of CD8+ "killer" T cells (one of the immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance a patient's immune response. Currently, Heat is conducting a Phase II trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small, cell lung cancer (NSCLC).
In addition to Heat's recent portfolio expansion due to the acquisition of Pelican Therapeutics, the company's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology Its current focus is on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
